Data reinforces the need for earlier CKD screening and earlier intervention
Findings from INSIDE-CKD demonstrate that Farxiga could cut 33 percent of healthcare costs by delaying disease progression and reducing incidence of cardiorenal events
AstraZeneca presented results at the American Society of Nephrology (ASN) Kidney Week Meeting from REVEAL-CKD and INSIDE-CKD which reinforce the urgent need for early screening of chronic kidney disease (CKD) and the benefits of earlier treatment initiation for patients and healthcare systems.
These findings were also simultaneously published in the Journal of the American Society of Nephrology.
While the results show an alarmingly high rate of undiagnosed Stage 3 CKD in multiple nations around the world, they also demonstrate an opportunity to greatly improve patient quality of life and reduce healthcare costs: data show a 33% cost reduction when patients were treated with Forxiga in addition to standard of care, compared with standard of care alone.
DAPA-CKD event rates were used to predict the incidence of included outcomes over a three-year horizon.
